UPB
Upstream Bio, Inc.
NASDAQ · USHealthcareBiotechnology
$6.98-0.43%
Price as of Jul 20, 2026
UPB profitability
Upstream Bio, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 98.5%
- EBITDA margin
- -4713.1%
- EBIT margin
- -5176.5%
- Net margin
- -4719.0%
- Free cash flow margin
- -4214.6%
Returns
- Return on equity
- -51.6%
- Return on assets
- -49.3%
- Return on invested capital
- -56.4%
- Asset turnover
- 0.01x
Cash efficiency
- Cash from operations
- -$140.0M
- Cash per share
- $5.41
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.